Sonographic markers of fetal aneuploidy

Clinics in Perinatology

Volumn 27, Issue 4, 2000, Pages 761-789

  Nyberg, David A ^a   Souter, Vivienne L ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

ANEUPLOIDY; CHROMOSOME ABERRATION; FAMILY HISTORY; FETUS; FETUS DISEASE; FETUS ECHOGRAPHY; FETUS RISK; FIRST TRIMESTER PREGNANCY; GENETIC RISK; GESTATIONAL AGE; HUMAN; MATERNAL AGE; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY;

EID: 0033637144     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(05)70052-X     Document Type: Article

References (154)

1. Prenatal ultrasonographic diagnosis of fetal heart echogenic foci: No correlation with Down syndrome
2. Fetal nuchal cystic hygromata. Associated malformations and chromosomal defects
3. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age
4. An alternative for women initially declining genetic amniocentesis. Individual Down syndrome odds on the basis of maternal age and multiple ultrasonographic markers
5. Ultrasonographically adjusted midtrimester risk of trisomy 21 and significant chromosomal defects in advanced maternal age
6. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results
7. First-trimester growth restriction and fetal aneuploidy. The effect of type and gestational age
8. Hyperechoic fetal bowel: The perinatal consequences
9. Gestational age standardized nuchal thickness values for estimating mid-trimester Down's syndrome risk
10. Can sonographers reliably identify anatomic features associated with Down syndrome in fetuses
11. Soft tissue nuchal fold in the second-trimester fetus. Standards for normal measurements compared with those in Down syndrome
12. Sonographic diagnosis of Down syndrome on the second trimester
13. Sonographic identification of second trimester fetuses with Down syndrome
14. Fetal pyelectasis: A possible association with Down syndrome
15. Identification of second-trimester fetuses with autosomal trisomy by use of a sonographic scoring index
16. Sonographic scoring index for prenatal detection of chromosomal abnormalities
17. J: Humeral shortening in second-trimester fetuses with Down syndrome
18. The value of echogenic foci ('golfballs') in the fetal heart as a marker of chromosomal abnormalities
19. First trimester fetal nuchal translucency. Problems with screening the general population
20. Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first trimester screening for trisomy 21
21. Early midtrimester fetal nuchal thickness. Effectiveness as a marker of Down syndrome
22. First-trimester Down's syndrome screening using nuchal translucency: A prospective study in patients undergoing chorionic villus sampling
23. Is fetal hyperechogenic bowel on second-trimester sonogram an indication for amniocentesis
24. Mild fetal lateral cerebral ventriculomegaly. Clinical course and outcome
25. The incorporation of maternal age into the sonographic scoring index for the detection at 14-20 weeks of fetuses with Down's syndrome
26. Choroid plexus cysts: Not associated with Down syndrome
27. Echogenic intracardiac focus. A sonographic sign for fetal Down syndrome
28. Significance of an echogenic intracardiac focus in fetuses at high and low risk for aneuploidy
29. The difference between septated and nonseptated nuchal cystic hygroma in the early second trimester
30. Left ventricular echogenic focus in the fetal heart. Pathologic correlation
31. Ultrasound findings and multiple marker screening in trisomy 18
32. Fetal pyelectasis and Down syndrome: Is genetic amniocentesis warranted
33. First-trimester screening for Down syndrome using nuchal translucency measurement with free B-hCG and PAPP-A between 10 and 13 weeks of pregnancy: The combined test
34. Trisomy 21: 91% detection rate using second-trimester ultrasound markers
35. The use of color Doppler ultrasound to identify fetuses at increased risk for trisomy 21. An alternative for high-risk patients who decline genetic amniocentesis
36. Prospective evaluation of the antenatal incidence and postnatal significance of the fetal echogenic cardiac focus. A case-control study
37. Prenatal sonographic detection of isolated fetal choroid plexus cysts. Should we screen for trisomy 18
38. Abnormal biochemical serum screening versus 2nd-trimester ultrasound-detected minor anomalies as predictors of aneuploidy in low-risk patients
39. First trimester sonographic detection of chromosomal abnormalities in an unselected population
40. Obstetric sonography. The best way to terrify a pregnant woman
41. Long-bone growth in fetuses with Down syndrome
42. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome
43. Isolated fetal choroid plexus cysts and trisomy 18: A review and meta-analysis
44. Clinical significance of fetal choroid plexus cysts
45. A Screening of maternal serum for fetal Down's syndrome in the first trimester
46. Screening for chromosomal abnormalities in an unselected population by nuchal translucency
47. Choroid plexus-ventricular wall separation in fetuses with normal-sized cerebral ventricles at sonograph. Postnatal outcome
48. The sonographic detection of trisomies 13, 18, and 21
49. Small hyperchoic foci of the fetal cardiac ventricle: A benign sonographic finding
50. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses
51. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation
52. Using nuchal translucency to screen for major cardiac defects at 10-14 weeks of gestation Population based cohort study
53. Intrauterine lethality of trisomy 21 fetuses with increased nuchal thickness
54. Early prenatal diagnosis of triploidy
55. Fetal heart rate and umbilico-placental Doppler flow velocity waveforms in early pregnancies with a chromosomal abnormality and/or increased nuchal translucency thickness
56. Combining humerus and femur length for improved ultrasonographic identification of pregnancies increased risk for trisomy 21
57. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination
58. Dysmorphologic features of the fetal pelvis in Down syndrome. Prenatal sonographic depiction and diagnostic implications of the iliac angle
59. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy on a routine ultrasound practice
60. Trisomy 13 syndrome Prenatal US findings in a review of 33 cases
61. Ear length in second-trimester aneuploid fetuses
62. The left ventricular echogenic focus: A normal finding
63. Gestational age standardized nuchal thickness values for estimating mid-trimester Down's syndrome risk
64. Mild idiopathic lateral cerebral ventricular dilatation in utero Sonographic evaluation
65. Significance of fetal intracardiac echogenic foci in relation to trisomy 21: A prospective sonographic study of high-risk pregnant women
66. Screening for chromosomal abnormalities at 10-14 weeks The role of ductus venosus blood flow
67. Triploidy. Antenatal sonographic features with post-mortem correlation
68. Down's syndrome, cardiac anomalies and nuchal translucency. Fetal heart failure might link nuchal translucency and Down's syndrome
69. Hyperechogenic fetal bowel. An ultrasonographic marker for adverse fetal and neonatal outcome
70. Nuchal thickening or cystic hygromas in first-and early second-trimester fetuses. Prognosis and outcome
71. Isolated choroid plexus cysts in the second-trimester fetus. Is amniocentesis really indicated
72. Strawberry-shaped skull in fetal trisomy 18
73. Ultrasonographically detectable markers of fetal chromosomal defects
74. Ultrasonographically detectable markers of fetal chromosomal abnormalities
75. Chromosome abnormalities
76. Echogenic fetal bowel: Clinical importance
77. Chromosomal abnormalities in fetuses with omphalocele. Significance of ompalocele contents
78. Prenatal sonographic findings of trisomy 18 Review of 47 cases
79. Role of prenatal ultrasound in women with positive screen for Down syndrome based on maternal serum markers
80. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: Description of the method and analysis of 142 cases
81. Enlarged cisterna magna and the Dandy-Walker malformation. Factors associated with chromosome abnormalities
82. Echogenic bowel and Down's syndrome
83. Humerus and femur length shortening on the detection of Down's syndrome
84. Prenatal sonographic findings of Down syndrome. Review of 94 cases
85. First trimester screening for fetal aneuploidy Biochemistry and nuchal translucency
86. The utility of fetal biometry as an adjunct to the multiple-marker screening test for Down syndrome
87. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population
88. Nuchal translucency thickness
89. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency
90. Fetal cerebral ventricular atrium: Difference in size according to sex
91. Unusual appearances of echogenic foci within the fetal heart. Are they benign
92. Natural history of echogenic foci within ventricles of the fetal heart
93. Ontogeny of clenchedhand development in trisomy 18 fetuses. A serial transabdominal fetoscopic observation
94. Fetal intracardiac echogenic foci. Does visualization depend on the orientation of the four-chamber view
95. Reinsch RC Choroid plexus cysts-association with trisomy. Prospective review of 16,059 patients
96. Cardiac histologic pathology characteristic of trisomies 13 and 21
97. Transvaginal ultrasound detection of septated and nonseptated cystic hygroma in early pregnancy
98. Prenatal sonographic findings in 187 fetuses with Down syndrome
99. In utero thickening of the chordae tendinae: A cause of intracardiac echogenic foci
100. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population
101. Second-trimester echogenic bowel and chromosomal abnormalities
102. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
103. Echogenic foci in the fetal heart. A marker of chromosomal abnormality
104. Second-trimester echogenic bowel and intraamniotic bleeding Association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 run
105. Ultrasonographic diagnosis of trisomy 18: Is it practical in the early second trimester
106. The frequency of fetal echogenic intracardiac foci with respect to maternal race
107. The iliac angle as a sonographic marker for Down syndrome in second-trimester fetuses
108. The significance of echogenic foci in the fetal heart. A prospective study of 228 cases
109. Fetal echogenic bowel on ultrasound: Is there clinical significance
110. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
111. Fetal exomphalos and chromosomal defects. Relationship to maternal age and gestation
112. Fetal choroid plexus cysts and trisomy 18. Assessment of risk based on ultrasound findings and maternal age
113. Maternal age- and gestation-specific risk for trisomy 21
114. Utility of minor ultrasonographic markers on the prediction of abnormal fetal karyotype at a prenatal diagnostic center
115. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation
116. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorioinic gonadotropin and pregnancy-associated plasma protein-A
117. Incidence of chromosomopathies and cystic fibrosis mutations in second trimester fetuses with isolated hyperechoic bowel
118. Choroid plexus cysts. Is biochemical testing a valuable adjunct to targeted ultrasonography
119. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age
120. Increased nuchal translucency as a marker for fetal chromosmal defects
121. Cut-off criteria for second-trimester nuchal skinfold thickness for prenatal detection of Down syndrome in a Thai population
122. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age
123. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
124. First-trimester midgut herniation. A high frequency sonographic study
125. Echogenic foci in the fetal heart: Incidence and association with chromosomal disease
126. Unfused amnion and chorion after 14 weeks of gestation: Associated fetal structural and chromosomal abnormalities
127. Dandy-Walker malformation diagnosed before 21 weeks of gestation. Associated malformations and chromosomal abnormalities
128. First-trimester sonography of physiological midgut herniation and early diagnosis of omphalocele
129. The role of ultrasonographic markers for trisomy 21 in women with positive serum biochemistry
130. Best second trimester sonographic markers for the detection of trisomy 21
131. Critical reappraisal of the utility of sonographic fetal femur length in the prediction of trisomy 21
132. Prevalence of aneuploidy with a cardiac intraventricular echogenic focus in at-risk patient population
133. Effect of ultrasound transducer frequency on the appearance of fetal bowel
134. Second-trimester ultrasound markers for detection of trisomy 21. Which markers are best?
135. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography
136. Indication-specific accuracy of second-trimester genetic ultrasonography for the detection of trisomy 21
137. Prenatal screening for Down's syndrome using inhibin-A as a serum marker
138. Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome
139. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
140. Isolated choroid plexus cysts. The need for routine offer of karyotyping
141. Fetal intracardiac echogenic foci. Does it matter which ventricle?
142. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population
143. The significance of choroid plexus cysts, echogenic heart foci and renal pyelectasis in the first trimester
144. Isolated fetal pyelectasis. Assessment of risk for postnatal uropathy and Down syndrome
145. Fetal pyelectasis. Comparison of postnatal renal pathology with unilateral and bilateral pyelectasis
146. The echogenic intracardiac focus in second trimester fetuses with trisomy 21. Usefulness as a US marker
147. Cerebellar and frontal lobe hypoplaslam fetuses with trisomy 21: Usefulness as combined US markers
148. Frontal lobe shortening in second-trimester fetuses with trisomy 21: Usefulness as a US marker
149. The role of midtrimester targeted fetal organ screening combined with the 'triple test' and maternal age in the diagnosis of trisomy 21. A retrospective study
150. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities
151. Iliac angle as a marker for Down syndrome in second-trimester fetuses: CT measurement
152. Can fetal iliac bone measurement be used as a marker for Down's syndrome screening